AEON Biopharma, Inc. (AEON)
| Previous Close | 1.5500 |
| Open | 1.5400 |
| Bid | 1.5400 x 900 |
| Ask | 1.6500 x 1200 |
| Day's Range | 1.5000 - 1.6900 |
| 52 Week Range | 1.2600 - 17.1700 |
| Volume | |
| Avg. Volume | 110,573 |
| Market Cap | 66.117M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipelineIRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization an
- GlobeNewswire
AEON Biopharma Reports First Quarter 2024 Financial Results
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s late-stage clinical pipeline for ABP-450 that targets multiple indications – IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatmen
- GlobeNewswire
AEON Biopharma Provides Update on Development Pipeline
Includes two late-stage clinical programs and two early-stage clinical programsIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our ear
